SCHEMBL6094948

SCHEMBL6094948

Cc1cc(CNC(=O)c2nc(N3CCCCC3CCO)n(C)c(=O)c2O)ccc1F

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 1/20 0.42
MMP13 P45452 8/20 0.41
CTNNB1 P35222 1/20 0.39
TCF7L2 Q9NQB0 1/20 0.39
KCNH2 Q12809 1/20 0.39
KCNE1 P15382 1/20 0.38
CCR1 P32246 1/20 0.38
KCNQ1 P51787 1/20 0.38
MMP10 P09238 3/20 0.36
MMP8 P22894 3/20 0.36
CALCA P06881 1/20 0.36
MMP9 P14780 1/20 0.35
CDK1 P06493 1/20 0.35
CDK2 P24941 1/20 0.35
CDK9 P50750 1/20 0.35
CDK5 Q00535 1/20 0.35
THRB P10828 1/20 0.34
KDM4E B2RXH2 1/20 0.34
ALDH1A1 P00352 1/20 0.34
LMNA P02545 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6096349 0.94 CYP2C9 (0.43) CYP2C9MMP13KCNH2KCNE1CCR1
SCHEMBL6096849 0.89 CYP2C9 (0.52) CYP2C9CTNNB1TCF7L2KCNH2KCNE1
SCHEMBL6093967 0.84 MMP13 (0.47) CYP2C9MMP13KCNH2KCNE1CCR1
SCHEMBL6094065 0.82 MMP13 (0.45) CYP2C9MMP13KCNH2KCNE1CCR1
SCHEMBL6094348 0.81 MMP13 (0.44) CYP2C9MMP13KCNH2KCNE1CCR1
SCHEMBL6087374 0.80 MMP13 (0.43) CYP2C9MMP13KCNH2KCNE1CCR1
SCHEMBL6095011 0.80 MMP13 (0.44) CYP2C9MMP13KCNH2KCNE1CCR1
SCHEMBL6093733 0.80 SOS1 (0.47) CYP2C9MMP13KCNH2KCNE1CCR1
SCHEMBL6087546 0.79 MMP13 (0.42) CYP2C9MMP13KCNH2KCNE1CCR1
SCHEMBL6094909 0.79 MMP13 (0.44) CYP2C9MMP13KCNH2KCNE1CCR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7135467-B2 Pyrimidine carboxamides; 5-hydroxy-2-(2-(1,1-Dioxo-6-[1,2]thiazinan-2-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamides; AIDS; AIDS related complex BRISTOL-MYERS SQUIBB COMPANY (US) 2006-11-14 US disclosed
US-20040204498-A1 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2004-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040204498-A1 HIV integrase inhibitors IMPDH1, TYMP, REV1 CYP2C9 701/4885MMP13 4367/4885CTNNB1 1691/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.